COVID-19 vaccine BNT162b1 elicits human antibody and T H 1 T cell responses.

Autor: Sahin U; BioNTech, Mainz, Germany. ugur.sahin@biontech.de.; TRON gGmbH-Translational Oncology at the University Medical Center of the Johannes Gutenberg, Mainz, Germany. ugur.sahin@biontech.de., Muik A; BioNTech, Mainz, Germany., Derhovanessian E; BioNTech, Mainz, Germany., Vogler I; BioNTech, Mainz, Germany., Kranz LM; BioNTech, Mainz, Germany., Vormehr M; BioNTech, Mainz, Germany., Baum A; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Pascal K; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Quandt J; BioNTech, Mainz, Germany., Maurus D; BioNTech, Mainz, Germany., Brachtendorf S; BioNTech, Mainz, Germany., Lörks V; BioNTech, Mainz, Germany., Sikorski J; BioNTech, Mainz, Germany., Hilker R; BioNTech, Mainz, Germany., Becker D; BioNTech, Mainz, Germany., Eller AK; BioNTech, Mainz, Germany., Grützner J; BioNTech, Mainz, Germany., Boesler C; BioNTech, Mainz, Germany., Rosenbaum C; BioNTech, Mainz, Germany., Kühnle MC; BioNTech, Mainz, Germany., Luxemburger U; BioNTech, Mainz, Germany., Kemmer-Brück A; BioNTech, Mainz, Germany., Langer D; BioNTech, Mainz, Germany., Bexon M; Bexon Clinical Consulting, Upper Montclair, NJ, USA., Bolte S; BioNTech, Mainz, Germany., Karikó K; BioNTech, Mainz, Germany., Palanche T; BioNTech, Mainz, Germany., Fischer B; BioNTech, Mainz, Germany., Schultz A; CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany., Shi PY; University of Texas Medical Branch, Galveston, TX, USA., Fontes-Garfias C; University of Texas Medical Branch, Galveston, TX, USA., Perez JL; Pfizer, Pearl River, NY, USA., Swanson KA; Pfizer, Pearl River, NY, USA., Loschko J; Pfizer, Pearl River, NY, USA., Scully IL; Pfizer, Pearl River, NY, USA., Cutler M; Pfizer, Pearl River, NY, USA., Kalina W; Pfizer, Pearl River, NY, USA., Kyratsous CA; Regeneron Pharmaceuticals, Tarrytown, NY, USA., Cooper D; Pfizer, Pearl River, NY, USA., Dormitzer PR; Pfizer, Pearl River, NY, USA., Jansen KU; Pfizer, Pearl River, NY, USA., Türeci Ö; BioNTech, Mainz, Germany.
Jazyk: angličtina
Zdroj: Nature [Nature] 2020 Oct; Vol. 586 (7830), pp. 594-599. Date of Electronic Publication: 2020 Sep 30.
DOI: 10.1038/s41586-020-2814-7
Abstrakt: An effective vaccine is needed to halt the spread of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic. Recently, we reported safety, tolerability and antibody response data from an ongoing placebo-controlled, observer-blinded phase I/II coronavirus disease 2019 (COVID-19) vaccine trial with BNT162b1, a lipid nanoparticle-formulated nucleoside-modified mRNA that encodes the receptor binding domain (RBD) of the SARS-CoV-2 spike protein 1 . Here we present antibody and T cell responses after vaccination with BNT162b1 from a second, non-randomized open-label phase I/II trial in healthy adults, 18-55 years of age. Two doses of 1-50 μg of BNT162b1 elicited robust CD4 + and CD8 + T cell responses and strong antibody responses, with RBD-binding IgG concentrations clearly above those seen in serum from a cohort of individuals who had recovered from COVID-19. Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were 0.7-fold (1-μg dose) to 3.5-fold (50-μg dose) those of the recovered individuals. Immune sera broadly neutralized pseudoviruses with diverse SARS-CoV-2 spike variants. Most participants had T helper type 1 (T H 1)-skewed T cell immune responses with RBD-specific CD8 + and CD4 + T cell expansion. Interferon-γ was produced by a large fraction of RBD-specific CD8 + and CD4 + T cells. The robust RBD-specific antibody, T cell and favourable cytokine responses induced by the BNT162b1 mRNA vaccine suggest that it has the potential to protect against COVID-19 through multiple beneficial mechanisms.
Databáze: MEDLINE
Externí odkaz: